{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ancillary+Study&page=34", "query": { "intervention": "Ancillary Study", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 2162, "total_pages": 217, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ancillary+Study&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ancillary+Study&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T04:01:09.535Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" }, { "nct_id": "NCT02516670", "title": "Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2016-06-20", "completion_date": "2021-10-14", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02516670" }, { "nct_id": "NCT01050842", "title": "Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer", "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "bicalutamide", "type": "DRUG" }, { "name": "raloxifene", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2010-02", "completion_date": "2012-10-04", "has_results": false, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01050842" }, { "nct_id": "NCT03398161", "title": "Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Localized Skin Lesion", "Mycosis Fungoides" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-01-06", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03398161" }, { "nct_id": "NCT02129569", "title": "Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Psychoeducational intervention", "type": "OTHER" }, { "name": "behavioral intervention", "type": "BEHAVIORAL" }, { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "telephone-based intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-11-11", "completion_date": "2016-08-17", "has_results": false, "last_update_posted_date": "2017-03-20", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02129569" }, { "nct_id": "NCT00899145", "title": "Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 0, "start_date": "2008-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-07-13", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899145" }, { "nct_id": "NCT04379570", "title": "Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2 Negative Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Text Message-based Navigation Intervention", "type": "OTHER" }, { "name": "Motivational Interviewing", "type": "BEHAVIORAL" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1167, "start_date": "2021-02-15", "completion_date": "2027-10-04", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 526, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379570" }, { "nct_id": "NCT01365169", "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Head and Neck Neoplasm", "Malignant Neoplasm", "Metastatic Malignant Neoplasm in the Neck", "Metastatic Malignant Neoplasm in the Uterine Cervix", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma", "Recurrent Colorectal Carcinoma", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Hypopharyngeal Carcinoma AJCC v7", "Stage I Major Salivary Gland Cancer AJCC v7", "Stage I Nasopharyngeal Carcinoma AJCC v7", "Stage I Oral Cavity Cancer AJCC v6 and v7", "Stage I Oropharyngeal Carcinoma AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7", "Stage II Major Salivary Gland Cancer AJCC v7", "Stage II Nasopharyngeal Carcinoma AJCC v7", "Stage II Oral Cavity Cancer AJCC v6 and v7", "Stage II Oropharyngeal Carcinoma AJCC v6 and v7", "Stage IIA Colorectal Cancer AJCC v7", "Stage IIB Colorectal Cancer AJCC v7", "Stage IIC Colorectal Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Hypopharyngeal Carcinoma AJCC v7", "Stage III Laryngeal Cancer AJCC v6 and v7", "Stage III Major Salivary Gland Cancer AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Oral Cavity Cancer AJCC v6 and v7", "Stage III Oropharyngeal Carcinoma AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Hypopharyngeal Carcinoma AJCC v7", "Stage IVA Laryngeal Cancer AJCC v7", "Stage IVA Major Salivary Gland Cancer AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVA Oropharyngeal Carcinoma AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Hypopharyngeal Carcinoma AJCC v7", "Stage IVB Laryngeal Cancer AJCC v7", "Stage IVB Major Salivary Gland Cancer AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oropharyngeal Carcinoma AJCC v7", "Metastatic or Locally Unresectable Solid Tumor" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Health Telemonitoring", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2011-05-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365169" }, { "nct_id": "NCT01077453", "title": "Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy, no Evidence of Disease", "Lobular Breast Carcinoma in Situ" ], "interventions": [ { "name": "letrozole", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 112, "start_date": "2010-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 3, "location_summary": "Tucson, Arizona • Rochester, Minnesota", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01077453" }, { "nct_id": "NCT07323641", "title": "Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Telisotuzumab Vedotin", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-19", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-22T04:01:09.535Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07323641" } ] }